Exploring the Growth of the Primary Immunodeficiency Disorders Global Market: A Forecast through 2025

Primary Immunodeficiency Disorders Global Market Report 2025

The Business Research Company's Primary Immunodeficiency Disorders Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 2, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

Globally, the primary immunodeficiency disorders market has exhibited robust growth in recent years. By 2025, the market size is expected to escalate from $6.84 billion in 2024 to $7.32 billion, reflecting a compound annual growth rate CAGR of 7.0%. The strong growth seen in the historic period can be ascribed to multiple factors such as rising incidences of primary immunodeficiency disorders, heightened awareness among healthcare professionals, a growing demand for effective treatment strategies, an increase in dedicated research funding, and an emphasis on improving pediatric care.

What's Fueling The Growth Of The Primary Immunodeficiency Disorders Market Going Forward?
In the coming years, it is anticipated that the primary immunodeficiency disorders market will maintain its steadfast growth trajectory. By 2029, the market size is expected to reach $9.51 billion, reflecting a robust CAGR of 6.8%. This substantial growth can be attributed to several interconnected factors such as upscaling adoption of subcutaneous therapies, improvements in healthcare accessibility, robust engagement in research and development, climbing need for efficient treatments, and burgeoning demand for immunoglobulin replacement therapy. The advent of innovative gene therapy and biologics, advancements in biotechnology, genetic testing and personalized medicine have all emerged as significant factors projected to influence the market trends in the forecast period.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp

What’s Driving The Primary Immunodeficiency Disorders Market Growth?
Rapidly escalating rates of autoimmune diseases are expected to play a prominent role in propelling the growth of the primary immunodeficiency disorders market, given that they cause an immune system malfunction wherein healthy cells and tissues are mistakenly attacked as foreign threats. These malfunctions can lead to primary immunodeficiency disorders by disrupting immune regulation and targeting immune cells, resulting in weakened or dysfunctional immune responses. Data obtained from Versorgungsatlas.de, a Germany-based interactive online platform, reveals that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease translating to a raw prevalence rate of 8.61%. This increasing prevalence of autoimmune diseases, driven by environmental triggers, genetic predispositions, and lifestyle changes, is a key factor in boosting the primary immunodeficiency disorders market.

What Key Player Strategies Are Driving The Primary Immunodeficiency Disorders Market?

The primary immunodeficiency disorders market boasts of prominent players such as Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., Chengdu Rongsheng Pharmaceutical Co Ltd.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/primary-immunodeficiency-disorders-global-market-report

What Are The Emerging Trends In The Primary Immunodeficiency Disorders Market?
Cutting-edge advancements in therapy modes were witnessed in this market with companies developing innovative methods like intravenous immunoglobulin therapy to enhance patient outcomes. Intravenous immunoglobulin IVIG therapy, a method where immunoglobulin derived from donor plasma is administered directly into a patient's bloodstream via an IV, is seen as a transformative treatment. Case in point, Grifols, a Spain-based healthcare company, received FDA approval for their IVIg therapy - Yimmugo, in June 2024.

How Is The Primary Immunodeficiency Disorders Market Segmented?
The market for primary immunodeficiency disorders can be segmented by diseases into antibody deficiency, cellular immunodeficiency and innate immune disorders. Treatments include immunoglobulin replacement therapy, antibiotic therapy, stem cell and bone marrow transplantation, gene therapy. Diagnostic methods like genetic testing, blood testing, flow cytometry are leveraged across hospitals, specialty clinics, homecare settings, and research institutions.

What Are The Regional Insights In The Primary Immunodeficiency Disorders Market?
Regionally, in 2024, North America emerged as the largest contributor to the primary immunodeficiency disorders market. Asia-Pacific is projected to emerge as the fastest-growing region over the forecast period while the market report covers regions like Western Europe, Eastern Europe, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Drugs for Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Cellular Immunotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.